The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis
Experimental & Molecular Medicine
;
: e40-2013.
Article
in English
| WPRIM
| ID: wpr-71809
ABSTRACT
In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body weight, bleeding score and stool score in addition to reversing DSS-induced mucosa destruction and shortened colon. The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. Mechanistically, WKYMVm effectively decreases intestinal permeability by stimulating colon epithelial cell proliferation. WKYMVm also strongly decreases interleukin-23 and transforming growth factor-beta production in the colon of DSS-treated mice. We suggest that the potent immune-modulating peptide WKYMVm and its receptor FPR2 may be useful in the development of efficient therapeutic agents against chronic intestinal inflammatory diseases.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oligopeptides
/
Permeability
/
Colitis, Ulcerative
/
Adjuvants, Immunologic
/
Transforming Growth Factor beta
/
Colon
/
Caco-2 Cells
/
Receptors, Formyl Peptide
/
Cell Proliferation
/
Interleukin-23
Limits:
Animals
/
Humans
Language:
English
Journal:
Experimental & Molecular Medicine
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS